Zhou Yuhang, Fang Chaoyou, Xu Houshi, Yuan Ling, Liu Yibo, Wang Xiaoyu, Zhang Anke, Shao Anwen, Zhou Danyang
Health Management Center, Tongde Hospital of Zhejiang Province, Hangzhou, China.
The First Clinical Medical College, Heilongjiang University of Chinese Medicine, Harbin, China.
Front Oncol. 2022 Sep 29;12:989896. doi: 10.3389/fonc.2022.989896. eCollection 2022.
Ferroptosis is a regulatory form of iron-dependent cell death caused by the accumulation of lipid-based reactive oxygen species (ROS) and differs from apoptosis, pyroptosis, and necrosis. Especially in neoplastic diseases, the susceptibility of tumor cells to ferroptosis affects prognosis and is associated with complex effects. Gliomas are the most common primary intracranial tumors, accounting for disease in 81% of patients with malignant brain tumors. An increasing number of studies have revealed the particular characteristics of iron metabolism in glioma cells. Therefore, agents that target a wide range of molecules involved in ferroptosis may regulate this process and enhance glioma treatment. Here, we review the underlying mechanisms of ferroptosis and summarize the potential therapeutic options for targeting ferroptosis in glioma.
铁死亡是一种由脂质活性氧（ROS）积累引起的铁依赖性细胞死亡的调控形式，与凋亡、焦亡和坏死不同。特别是在肿瘤性疾病中，肿瘤细胞对铁死亡的易感性影响预后，并与复杂的效应相关。胶质瘤是最常见的原发性颅内肿瘤，占恶性脑肿瘤患者的81%。越来越多的研究揭示了胶质瘤细胞中铁代谢的特殊特征。因此，靶向参与铁死亡的多种分子的药物可能调节这一过程并增强胶质瘤治疗效果。在此，我们综述铁死亡的潜在机制，并总结靶向胶质瘤中铁死亡的潜在治疗选择。
